Shattuck Labs Inc Dossier
Qualitative Analysis
Business overview
Shattuck Labs, Inc. (NASDAQ: STTK) is a clinical-stage biotechnology company pioneering the development of potentially first-in-class monoclonal and bispecific antibodies targeting the tumor necrosis factor (TNF) receptor superfamily. The company's core scientific focus centers on the clinically validated DR3/TL1A pathway to treat patients with inflammatory and immune-mediated diseases, such as Inflammatory Bowel Disease (IBD). Shattuck's lead clinical candidate is SL-325, a potentially first-in-class DR3 antagonist antibody designed to achieve a complete and durable blockade of the TL1A/DR3 pathway. Shattuck is also developing SL-425, a half-life extended version of SL-325, alongside preclinical DR3-based bispecific antibodies and its oncology-focused TRIM7 program.
Research as of 20 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Advancing SL-325, a potentially first-in-class Death Receptor 3 (DR3) blocking antibody designed to achieve a complete and durable blockade of the clinically validated DR3/TL1A pathway for inflammatory bowel disease (IBD). Following positive Phase 1 results in healthy volunteers, the company is preparing to launch a Phase 2b trial in Crohn's disease.
Expected impact: Establish clinical efficacy and a best-in-mechanism immunogenicity profile in patients with moderate-to-severe Crohn's disease.
Developing SL-846, a bispecific antibody candidate designed to inhibit both the DR3/TL1A axis and the IL-23 receptor (IL-23R) for the treatment of inflammatory and immune-mediated diseases.
Expected impact: Expand the pipeline with a next-generation bispecific candidate that could improve upon the efficacy of single-pathway TL1A inhibitors.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations